Objective:To observe the therapeutic effect of acupuncture plus medication in the treatment of mild cognitive impairment of liver-kidney insufficiency type.
Summary. To study the effect of Cytoflavin on parameters of systolic left ventricular function in acute myocardial infarction. 46 patients with standard therapy received the drug Сytoflavin (Polysan, St.Petersburg, Russia) intravenously 20 ml of the solution diluted in 250 ml 5% glucose solution, 1 times a day 30 minutes before coronary artery recanalization; 60 patients (control group) received only standard therapy. The drug's effectiveness was evaluated in terms of systolic left ventricular function: ejection fraction, end-diastolic volume, end-systolic volume. The inclusion of Сytoflavin in the treatment of patients with acute myocardial infarction should be considered as pathogenetically justified clinically justified and promising.
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Myocardial ischemic injury, currently occupying a leading position in the rank of priority problems of cardiology, is one of the most frequent causes of myocardial infarction, which occurs circulatory disorders are crucial for the disease and for the nearest and remote forecast of life of patients with a high early morbidity and mortality. In addition to ischemic myocardial damage, severity of acute myocardial infarction is determined by the degree of metabolic disorders caused by the reduction of the heart. On the one hand, the depth of metabolic disorders caused by a primary lesion of the myocardium and are associated with these disorders of the Central hemodynamics, hypoxia and the body's reaction to damage to the heart muscle; on the other hand, secondary metabolic disorders could exacerbate violations of the contractility of the heart and to influence the outcome of the disease. This leads to the desirability of finding means of pharmacological correction of hypoxic and metabolic disorders, to their use in the early stages of myocardial ischemia.
In recent years, in complex therapy of myocardial ischemia include combination drug Cytoflavin developed "POLYSAN" (Saint-Petersburg, Russia), which is composed of riboxin, riboflavin, nicotinamide, succinic acid. Despite a few articles that reflect the results of clinical trials succinaldehyde of the drug in complex therapy of myocardial infarction, searching for new evidence of the efficacy of Cytoflavin as an adjuvant pharmacological component of reperfusion therapy is in our view a promising and reasonable.
Materials and methods. To study the effect of Cytoflavin on parameters of systolic left ventricular function in acute myocardial infarction. 46 patients with standard therapy received the drug Сytoflavin (Polysan, St.Petersburg, Russia) intravenously 20 ml of the solution diluted in 250 ml 5% glucose solution, 1 times a day 30 minutes before coronary artery recanalization; 60 patients (control group) received only standard therapy. The drug's effectiveness was evaluated in terms of systolic left ventricular function: ejection fraction, end-diastolic volume, end-systolic volume.
The introduction of Cytoflavin patients contributed to an increase in ejection fraction of the left ventricle of 7.9% compared to the same indicator in the patients of the control group, reduced end-diastolic and end-systolic volume of the left ventricle by 10.6% and 17.9% respectively on day 7 of hospitalization (р≤0,05). Addition to standard therapy with Cytoflavin significantly reduced the level of troponin I in patients with acute myocardial infarction on day 7 for 81% relative to the control, the activity of creatine kinase -35% (р≤0,05).
The inclusion of Сytoflavin in the treatment of patients with acute myocardial infarction should be considered as pathogenetically justified clinically justified and promising.
Intravenous drip for patients with acute myocardial infarction Cytoflavin 30 minutes before coronary artery recanalization on the background of standard therapy promotes the positive dynamics of systolic left ventricular function with increased ejection fraction of the left ventricle, reducing end-diastolic and end-systolic volume of the left ventricle in comparison with similar indicators of control group on day 7 of hospitalization. Inclusion in standard therapy of acute myocardial infarction succinaldehyde of the drug Cytoflavin significantly reduces the level of troponin I and activity of creatine kinase in the blood of patients with myocardial infarction on day 7 relative to the patients of the control group.
